The pyrrolopyrimidine U101033E is a therapeutic compound potentially useful in stroke, head injury and other oxidative stress conditions. Electron paramagnetic resonance (EPR) techniques of spin labeling and spin trapping in conjunction with measures of lipid and protein oxidation have been used to investigate the proposed antioxidant capacity of U101033E. We report potent antioxidant activity of this agent in aqueous cell-free solution as measured by spin trapping. U101033E significantly (P 6 0.005) reduces the formation of the EPR active spin trap N-t-butyl-K-phenylnitrone (PBN)-radical adduct by 17.1% at a concentration of 1 WM, four orders of magnitude less than the concentration of PBN. As measured by the decrease in signal intensity of lipid-resident nitroxide stearate spin probes, an EPR assay for lipid peroxidation, this pyrrolopyrimidine compound efficiently protected against hydroxyl radical-induced lipid peroxidation in cortical synaptosomal membranes deep within the membrane bilayer, but not closer to the membrane surface. In addition, U101033E partially prevents synaptosomal protein oxidation in the presence of Fe(II); however, U101033E demonstrates some protein oxidative effects itself. These results are supportive of the proposed role of U101033E as a lipid-specific antioxidant, especially for protection against lipid peroxidation that occurs deep within the membrane bilayer, but raise some potential concerns about the oxidative nature of this agent toward proteins. ß
Introduction
Increasing evidence continues to implicate oxidative stress in the neurodegenerative cascades linked to various central nervous system (CNS) disorders. Neuronal dysfunction associated with disorders such as Alzheimer's disease (AD) and following an insult such as ischemia/reperfusion has been found to correlate with oxidative damage in clinical and model systems [1^3] . Antioxidants are reported to o¡er protection against oxidative damage in these disorders [4^9] .
Among major biomarkers for oxidative damage are lipid peroxidation products, especially 4-hydroxy-2-trans-nonenal (HNE), which is thought to play an important role as a mediator of free radical-induced neurotoxicity [10] . The amyloid-betapeptide (AL), found as the major constituent of senile plaques in the AD brain, has been shown to generate free radicals [11^13] and thus contributes to the oxidative stress environment found in the AD brain. AL initiates lipid peroxidation that leads to HNE formation [14, 15] , which has been suggested to mediate the toxic e¡ects of the peptide [15^18] . Increased levels of free and bound HNE have been found in the AD brain and cerebro-spinal £uid (CSF) [19^23] . Free radical-induced lipid peroxidation has also been shown to be responsible for much of the damage incurred after an ischemic insult [24] , as well as in other disorders [25] . Diminished lipid damage following the administration of lipophilic antioxidants results in neuroprotection [1,5,26^29] , suggesting the importance of these free radical scavengers in neuronal injury. Studies such as these further promote the role of lipid peroxidation products, especially HNE, in the neurodegenerative cascade.
That oxidative lesions and lipid peroxidation products are increased in neurological disorders and that antioxidants have been shown to diminish the formation of both suggests that antioxidative therapeutics may be bene¢cial in these disorders. Protection of neuronal membranes by lipophilic antioxidants would quench the initiation of the oxidative process and eliminate any resulting damage. Preincubation with antioxidants such as vitamin E, estrogen and glutathione has provided protection against radicalinduced injury [5,8,9,28^30] . The pyrrolopyrimidines are a relatively new class of proposed therapeutics for the prevention of free radical-induced damage, especially lipid peroxidation. In several models of oxidative stress-induced cellular injury, including ischemia/reperfusion, a pre-administration of the pyrrolopyrimidines, especially U101033E ( Fig. 1) , has resulted in signi¢cantly diminished neuronal damage [1,26,27,31^38 ].
In the current study, the means by which U101033E mediates its protective e¡ects were investigated. The free radical scavenging capabilities of U101033E were determined using an aqueous electron paramagnetic resonance (EPR) spin trapping assay. Protection from hydroxyl free radicals by U101033E was also investigated in cortical synaptosomal preparations. Oxidative modi¢cations of synaptosomal proteins by hydroxyl radicals, manifested as protein carbonyls and the induction of protein conformational changes were examined by Western immunoblotting and EPR spin labeling techniques, respectively. In addition, U101033E was tested for its ability to quench hydroxyl radical-induced lipid peroxidation in synaptosomal membranes by monitoring the EPR signal intensity of the lipid-speci¢c spin probes, 5-nitroxide stearate (NS) and 12-NS.
Materials and methods

Chemicals
Protease inhibitors were purchased from ICN. U101033E was a generous gift from E.D. Hall (then at Pharmacia-Upjohn). An Oxyblot kit was obtained from Encor. PBN (N-t-butyl-K-phenylnitrone) was synthesized as described by Huie et al. [39] , repeatedly recrystallized and sublimed and purity demonstrated by high performance liquid chromatography, nuclear magnetic resonance and EPR. Nitrocellulose membranes and transfer ¢lter papers were purchased from Bio-Rad. All other chemicals were obtained from Sigma in highest purity.
Synaptosomal preparation
Synaptosomes were prepared as described previously [40] . Gerbils were decapitated, the brain re- moved quickly and put on ice. Each cortex was dissected and immediately suspended in ice-cold isolation bu¡er containing: 0.32 M sucrose containing 4 Wg/ml leupeptin, 4 Wg/ml pepstatin, 5 Wg/ml aprotinin, 20 Wg/ml trypsin inhibitor, 0.2 mM phenyl methyl sulfonyl £uoride (PMSF), 2 mM ethylenediamine tetraacetic acid (EDTA), 2 mM ethyleneglycol bistetraacetic acid (EGTA) and 20 mM 4-(2-hydroxyyethyl)-1-piperazineethane sulfonic acid (HEPES). All cortices were then homogenized by 12 passes with a motor driven te£on pestle. The homogenate was centrifuged at 3800 rpm (1500Ug) for 10 min. Discarding the pellet, the supernatant was collected and centrifuged at 14 800 rpm (20 000Ug) for 10 min. The supernatant was removed and the pellet resuspended in isolation bu¡er. This resuspension was layered onto discontinuous gradients containing 10 ml each of 1.18, 1.0 and 0.85 M sucrose solutions each with 2 mM EDTA, 2 mM EGTA and 10 mM HEPES (pH 8.0 for 0.85 and 1.0 M solutions, pH 8.5 for 1.18 M solution). Samples were spun in a Beckman L7-55 ultracentrifuge at 22 000 rpm (82 500Ug) for 2 h at 4³C. The resulting puri¢ed synaptosomal vesicles were removed from the 1.18/1.0 M interface and subsequently lysed and washed twice with lysing bu¡er (2 mM EDTA, 2 mM EGTA, 10 mM HEPES, pH 7.4). All centrifugations were performed at 4³C. The total protein concentration was determined by the method of Lowry et al. [41] and all samples were adjusted to a concentration of 4 mg/ml.
EPR and spin trapping
PBN was used as the spin trap in an aqueous spin trapping assay. PBN was dissolved in H 2 O as a 50 mM stock solution, with a 10 mM ¢nal concentration in all samples. The Fenton reaction was used as the radical generating system with ¢nal concentrations of Fe(II) and H 2 O 2 being 30 WM and 3 mM, respectively. All reagents, except hydrogen peroxide, were added, the samples were vortexed to ensure complete mixing and were again vortexed after the addition of hydrogen peroxide. Each reaction was allowed to incubate for 30 min at room temperature before being stopped with the addition of 2 mM deferoxamine, an iron ion-chelating reagent. U101033E was added in volumes of 10 Wl from stock solutions of 100, 10, 1 and 0.1 mM in dimethyl sulfoxide (DMSO), giving ¢nal concentrations of 1, 0.1, 0.01 and 0.001 mM, respectively. All control samples contained 1% DMSO. EPR spectra were acquired on a Bruker EMX spectrometer with the following instrumental parameters: microwave frequency, 9.77 GHz; microwave power, 20 mW; receiver gain, 1U10 5 ; modulation amplitude, 0.3 G and time constant, 1.28 ms.
Oxidative treatment and spin labeling
For protein oxidation studies, samples were treated with U101033E or the corresponding volume of vehicle (DMSO), mixed gently and incubated for 30 min at room temperature. The samples were then divided into two equal portions and oxidants added to one portion and the corresponding volume of bu¡er added to the second portion. Oxidation was accomplished by addition of 30 WM Fe(II) to synaptosomes, which contain intrinsic H 2 O 2 [42] and 3 mM ascorbic acid, to keep Fe(II) in the reduced state. Samples were again mixed gently and incubated at room temperature. After 30 min, the samples were washed three times in lysing bu¡er to remove excess oxidants. For all dose response studies, U101033E was incubated in synaptosomes at room temperature for 1 h.
Following oxidative treatments, samples were analyzed for changes in protein conformation by EPR after being labeled with the paramagnetic proteinspeci¢c spin label Mal-6 (2,2,6,6-tetramethyl-4-maleimidopiperidin-1-oxyl) [43^46]. Mal-6 (2.5 mg) was dissolved in 100 Wl of acetonitrile and diluted to 50 ml in lysing bu¡er. Samples were labeled by incubating 12.5 Wg Mal-6/mg of protein ([50 WM] ¢nal concentration) for 16 h at 4³C [46] . Samples were pelleted in a refrigerated Eppendorf table-top centrifuge, the supernatant removed and the pellet resuspended in 1 ml of fresh lysing bu¡er. This washing cycle was repeated six times to ensure complete removal of all unbound spin label before acquiring EPR spectra.
The analysis of lipid peroxidation was performed in conjunction with the lipid-speci¢c spin probes, 5-NS and 12-NS. Samples were incubated for 1 h at room temperature by gentle shaking in culture tubes coated with 6 Wg of 5-or 12-NS/mg of protein. The samples were then taken for EPR analysis as indi-cated above. Following acquisition of the initial spectrum, each sample was removed from the quartz £at cell for aqueous samples and mixed with Fe(II) (30 WM), U101033E or vehicle. In samples receiving treatment with U101033E (or vehicle) and Fe(II), the former was incubated for 30 min prior to addition of Fe(II). The sample was mixed and immediately returned to EPR in order to monitor the decrease of signal intensity with time.
Western blotting
Protein carbonyls are an index of protein oxidation [47] . The method of detection in this study was by Western blot analysis of the 2,4-dinitrophenyl hydrazone (DNP) adduct of the carbonyls. Sample aliquots (30 Wg protein) were incubated with 2,4-dinitrophenylhydrazine in the presence of SDS for 20 min at room temperature and quenched by the addition of a neutralization solution. Proteins were separated by non-reducing SDS^PAGE according to Laemmli et al. [48] using 4.6 and 12.5% acrylamide stacking and separating gels, respectively. Care was taken to load the same amount of protein to each lane on the gel and protein amounts in each lane were determined by Coomassie staining. Proteins were electroblotted onto a nitrocellulose membrane and analyzed colorimetrically by employing a rabbit antibody speci¢c for 2,4-dinitrophenylhydrazone protein adducts and an alkaline-phosphatase conjugated IgG (goat anti-rabbit) using BCIP/NBT as substrate. Levels of DNPH reactivity were digitized and quantitated using computer-assisted imaging with MCID/M4 software supplied by Imaging Research (St. Catharine's, Ont., Canada).
Results
Spin trapping
The EPR method of spin trapping involves the use of an EPR-silent`spin trap' and some source of transient free radicals (reviewed in [49, 50] ). In our spin trapping assay, PBN was used as the trap while Fenton chemistry was used to generate hydroxyl radicals. The reaction of radicals with the nitrone spin trap produces EPR active nitroxide spin adducts.
The spin adducts are much more stable than their short-lived parent radicals and can therefore be quantitated by EPR spectroscopy.
These spin trapping methods were used to determine directly the free radical scavenging ability of U101033E and for this reason were performed in an aqueous cell-free system containing only the nitrone trap, the radical generating system and the drug or vehicle. In all spin trapping experiments conducted, the DMSO was held constant (1%). In the absence of U101033E, a 6-line EPR spectrum is observed (A N = 15.08 G, A H = 3.38 G) which is compar- An 81.8% decrease in signal intensity results in the presence of 10 WM U101033E, three orders of magnitude less than the concentration of PBN. (C) Increasing concentrations of U101033E result in the elimination of PBN trapped radicals as shown by larger % decreases in EPR signal (n = 6; *P 6 0.005; **P 6 0.001; Student's paired t-test).
able with reports of a PBN-DMSO adduct [51] . A dramatic decrease in PBN trapped radical, observed as a decrease in EPR signal intensity of the 6-line spectrum, was found in the presence of U101033E (Fig. 2) . Concentrations as low as 1 WM resulted in a signi¢cant reduction (17.1%, P 6 0.005) in the EPR signal intensity. These results indicate the potent ability of the pyrrolopyrimidine U101033E to scavenge radicals.
Analysis of lipid peroxidation
The reduction of the EPR signal intensity of the NS spin probes in neuronal membranes has been used as a model of lipid oxidation and as an assay for the radical scavenging ability of antioxidant compounds [14, 29, 52] . The reaction of nitroxide spin probes with some transient free radical results in the formation of the non-paramagnetic hydroxylamine and a consequent loss in EPR signal intensity. The generation of hydroxyl radicals in our experiments with synaptosomes likely leads to the formation of carbon centered lipid radicals (and the initiation of lipid peroxidation) that can react directly with nitroxide probes. It is in this sense that the radical-induced reduction of NS spin probes mimics lipid oxidation. Radical scavenging compounds that intercept these radicals (and also lipid peroxyl radicals) before the chemical reduction of the nitroxide prevent the loss of EPR signal intensity and are likely to have quenched the lipid peroxidative chain reaction. 5-NS contains a nitroxide group on the 5th carbon of the stearic acid acyl chain, whereas the nitroxide is on the 12th carbon of 12-NS. This selectivity allows one to probe di¡erent regions of the C Fig. 3 . The reduction of NS EPR signal intensity following the addition of Fe(II) is indicative of lipid peroxidation. After incubation with NS, synaptosomes were treated with 30 WM Fe(II) to initiate radical generation and a decrease in NS signal intensity. In determining protective e¡ects, U101033E (or DMSO) was incubated 30 min prior to addition of Fe(II). Overlapping EPR spectra of (A) 5-NS and (B) 12-NS controls before and after addition of Fe(II). The arrow indicates the loss of signal intensity that is measured as an index of lipid oxidation. (C) In the presence of Fe(II), 5-NS signal intensity is decreased by 41.7%. There is a similar loss of signal intensity after a pre-incubation with 100 WM U101033E indicating a lack of protection against lipid peroxidation. (D) The decrease in 12-NS signal intensity by Fe(II) is 19.1%. In the presence of 100 WM U101033E, the loss of signal intensity by iron-induced hydroxyl radicals is essentially eliminated indicating protection against lipid peroxidation. No decrease of NS intensity was observed in the presence of U101033E or DMSO, while the decrease of signal intensity in oxidized, vehicle-treated samples were of similar magnitude as that of oxidized controls. Dotted lines represent unoxidized control values (n = 3^4; *P 6 0.05; Student's paired t-test).
membrane; 5-NS is close to the aqueous/lipid interface and 12-NS is deeper within the bilayer [46] .
The loss of 5-NS signal intensity in synaptosomes after the generation of hydroxyl radicals suggests that lipid oxidation has occurred which results in the quenching of the paramagnetism of the NS probe (Fig. 3A) . No protection of lipid oxidation was afforded by the presence of U101033E as is evident by a loss in 5-NS signal intensity comparable to that observed in controls. In contrast to the 5-NS results, 100 WM U101033E, a concentration reported to be e¡ective against lipid peroxidation [1] , essentially completely prevents the decrease of the 12-NS signal induced by hydroxyl free radicals (Fig. 3B ). This latter result is consistent with the proposed mechanism of protection a¡orded by U101033E and other analogous pyrrolopyrimidines [1] , as well as other reports of protection from lipid peroxidation [26, 33] .
U101033E induces protein conformational changes
In addition to protection against lipid peroxidation, we investigated whether U101033E would protect synaptosomes against hydroxyl radical-induced protein oxidation. The paramagnetic spin label Mal-6 binds predominantly to protein thiol residues giving information about protein conformations.
Mal-6 bound to protein thiols can be classi¢ed into two main environments with respect to the motion of the spin label: weakly (W)-and strongly (S)-immobilized [43^46]. The motion of Mal-6 bound to W sites is only weakly restricted, which is manifested as narrow lines in the EPR spectrum. In contrast, the Mal-6 bound to S sites have strongly hindered motion, which is manifested as broadened lines in the Fig. 4 . The pyrrolopyrimidine U101033E induces conformational changes in synaptosomal membrane proteins. Increasing concentrations of U101033E induce changes in protein conformation as deduced from decreases in the W/S ratio (n = 10; *P 6 0.001; **P 6 0.0001; Student's paired t-test). A pretreatment of 100 WM U101033E causes a similar decrease in the W/S ratio, while only a small further decrease is observed after these U101033E-treated samples were treated with Fe(II). (Both of these changes are signi¢cant from vehicletreated, unoxidized control.) (B) A normalization of the data in (A) to their respective controls reveals a signi¢cant di¡erence in the decrease of the W/S ratio after oxidation that is dependent on the presence or absence of U101033E. Dotted line represents normalized control values. Black bars represent unoxidized samples whereas gray bars represent oxidized samples (n = 6; *P 6 0.0001 with respect to unoxidized vehicle; **P 6 0.01 with respect to both oxidized vehicle and unoxidized, U101033E-treated samples; Student's paired t-test).
EPR spectrum. The resulting intensities of the respective W and S peaks of the M I = +1 low-¢eld resonance line give rise to the W/S ratio, which is highly sensitive to protein conformational changes [3,28,42^46] . Decreased values of the W/S ratio arise from increased protein^protein interactions or decreased segmental motion of spin labeled proteins and are lowered in synaptosomes following protein oxidation [3, 16, 28, 30, 42] .
Even in the absence of Fe(II), 100 WM U101033E caused a signi¢cant 12.0% decrease (P 6 0.001) in the W/S ratio, while lower concentrations induced insigni¢cant changes from control values that were similar in magnitude to those induced by the vehicle (Fig. 4) . This result suggests that U101033E induces physical changes in synaptosomal protein structure. The decrement of W/S in samples that had been incubated with the drug (100 WM) were of similar magnitude to those changes seen in vehicle-treated samples that received oxidative treatments (Fig. 5A ). There seems to be no di¡erence in the W/S ratio in oxidized samples pretreated with U101033E when compared to oxidized samples pretreated with vehicle only. However, there is a signi¢cant di¡erence (P 6 0.01) in Fe(II)-induced decrease in the W/S ratio when samples in Fig. 5A are normalized to their respective controls (Fig. 5B) . These data suggest that U101033E initiates some physical changes in protein structure in the absence of an additional oxidative stimulus, but that the drug partially prevents further radical-induced damage, presumably by way of its radical-scavenging ability.
Analysis of protein carbonyls
The incorporation of carbonyl groups into a protein backbone or side chains has become widely recognized as a marker of increased protein oxidation [47, 53] . Sensitive immunochemical methods for the analysis of protein carbonyl formation in the presence of oxidative environments are available and were used in this study to determine the e¡ect U101033E had on hydroxyl radical-induced increases in protein carbonyls. Immunoblot analysis indicates that U101033E, in the absence of additional oxidative stimulation, promotes the formation of protein carbonyls in a concentration dependent manner (Fig.  6 ). At a concentration of 100 WM, U101033E in- duced a 19.9% increase (P 6 0.01) in synaptosomal protein carbonyl groups and at extremely high concentrations caused an increase in protein cross-linking that resulted in high molecular weight aggregates and a concomitant loss of lower molecular weight proteins (Fig. 7) . Increased oxidation leads to changes in protein structure [54] , and these current results are consistent with the e¡ects U101033E has on protein conformation determined by EPR: increased protein aggregation leads to decreased segmental motion and correspondingly to decreased W/S ratios of Mal-6 labeled proteins. In the presence of generated free radicals, samples pretreated with U101033E seemed to show no protection from carbonyl formation when compared to untreated controls (Fig. 8A) . However, when normalized to its respective control, a pretreatment of 100 WM U101033E eliminates any additional hydroxyl radical-induced protein oxidation (Fig. 8B) . These data, in agreement with our protein conformational studies, suggest that the radical scavenging abilities of U101033E do protect the proteins from damage, but only after the proteins have been altered by the drug itself.
Discussion
The pyrrolopyrimidines have been proposed as potent lipid peroxidation inhibitors and have proven to be e¡ective protectants in several di¡erent models [1] . For example, several pyrrolopyrimidine variants, including U101033E, have a¡orded protection in various models of ischemia/reperfusion as measured by infarct area [1,35^37] and neurological recovery [1, 35, 36] . U101033E protects against hydroxyl radical-induced lipid peroxidation and peroxynitrite toxicity in cultured neurons [27] and prevents peroxynitrite-induced tyrosine nitration and Fe (II)/EDTAinduced HNE formation in human erythrocyte membranes [33, 34] . Although U101033E has provided signi¢cant protection against a variety of insults, its mechanism of action remains to be de¢ned.
The present study demonstrates the radical scavenging ability of U101033E as assessed by an aqueous cell-free EPR spin trapping assay (Fig. 2) . A decreased amount of PBN-radical adduct formation, manifested as a decrease in EPR signal intensity, was observed in the presence of U101033E. There was an approximate two-fold decrease in signal intensity for every mole of U101033E in samples with concentrations less than the 30 WM of hydroxyl radicals produced. That the decrease in signal intensity was approximately double the expected value is consistent with the antioxidative mechanism of U101033E proposed by Hall et al. [1] , which involves initial radical quenching by electron donation and secondary radical trapping.
It is plausible that the DMSO in which the drug is delivered interferes with the determination of hydroxyl radical trapping by U101033E in this assay. DMSO, which has been shown to be a radical scavenger [55] , is in signi¢cant molar excess (140 mM) as compared to PBN (10 mM). The hydroxyl radical is extremely reactive and its reactivity is limited only by di¡usion and, therefore, the hydroxyl radicals produced conceivably could react with DMSO before they react with PBN or U101033E. In fact, the DMSO-derived radical formed in the presence of hydroxyl radicals has been shown to react with PBN [56] . The coupling constants from our spin trapping experiments are equivalent to those of a DMSO-derived radical and, in this scenario, the elimination of signal by the drug would be due to the scavenging of DMSO radicals. In all spin trapping experiments conducted in this study the DMSO concentration was held constant, yet the EPR signal decreased with increasing drug concentration. Therefore it is the drug, and not DMSO, that is responsible for the decrement in the observed signal, i.e. the drug is a potent radical scavenger. The NS reduction model of lipid peroxidation is a highly sensitive measure of lipid oxidation [14, 29, 52] . EPR spin labeling directly measures the presence of stable free radical species, while the reduction of the NS signal intensity must involve some transient free radical species, likely either a carbon-centered or lipid peroxyl radical in these experiments, that react with the paramagnetic center of the spin label. The production of hydroxyl radicals will, by hydrogen atom abstraction, initiate the propagation of lipid radicals within the bilayer. These lipid radicals, by reacting with molecular oxygen, can then form lipid peroxides and hydroperoxides, which perturb membrane structure and function [46, 57] and have been implicated in signal transduction processes that may result in apoptotic cell death [58, 59] . Lipid peroxides are able to form, through various reactions and rearrangements, a multitude of lipid peroxidation products, including HNE [10] . Di¡erences in lipid structure, e.g. sites of unsaturation, result in di¡erent rates of lipid peroxidation [57] . Unsaturated sites are susceptible to peroxidation, which is attributed to increased stability of the allylic carbon radical through conjugation and thus have a longer lifetime with which to react with oxygen. The di¡erence in position of the nitroxide spin label on the stearic acid acyl chain allows for the determination of radical scavenging close to the phopholipid head groups (5-NS) or deeper within the bilayer (12-NS), the latter near the most common sites of unsaturation. The U101033E-mediated prevention of hydroxyl radicalinduced signal intensity loss in the 12-NS, but not the 5-NS system, suggests that U101033E may be localized in the membrane. This localization leads to the scavenging of radicals in an area of the membrane where HNE and other lipid peroxidation products are likely to be formed [60] , but probably not closer to the lipid/aqueous interface.
Protein oxidation results in altered protein structure and function [54] , that causes changes in enzymatic activity [53, 54, 61] and loss of cellular homeostatic control that ultimately leads to cellular dysfunction [62] . Because protein oxidation occurs in such oxidative events as ischemia [63] and due to the known protection of the pyrrolopyrimidines against ischemia [1] , we reasoned that U101033E may prevent the oxidation of proteins. However, in our hands, U101033E induces protein oxidation and conformational changes when incubated in synaptosomal preparations (Fig. 6 ). This e¡ect increases with increasing concentration of the drug while promoting protein^protein cross-linking at extreme (10 mM) concentrations (Fig. 7) . These excessive concentrations are unlikely to be used in in-vivo models where protection is a¡orded at much lower doses [1] , but may be important in determining the mechanism of action of U101033E; i.e. electron donation by U101033E may account for its oxidative e¡ects on these proteins. Further, protein conformational changes, resulting in changes in the orientation rate of protein-bound Mal-6 residues, have been previously correlated with increases in protein carbonyl formation [3, 28, 40, 63] and are similar to our current ¢ndings. The pro-oxidant activity of U101033E may also play a role in its e¡ects on synaptosomal protein conformations. However, these questions were not directly addressed in this study.
At ¢rst glance our results seem to suggest that U101033E has little protective e¡ect against oxidative damage to synaptosomal proteins. However, when determining whether U101033E protected synaptosomal proteins from hydroxyl radical-induced damage, samples were pre-incubated with the drug before exposure to oxidation. Thus, any changes in protein carbonyl content or conformation induced by U101033E may have occurred prior to the addition of oxidants. After normalizing the data to each respective control, it was evident that Fe(II)-dependent protein oxidation in the presence of U101033E was di¡erent from untreated, oxidized controls (Fig. 8B) . In similar fashion, after the initial change induced by U101033E, only small changes in protein conformation take place after incubation with oxidants (Fig.  5B) . This result suggests that U101033E does partially protect against hydroxyl radical-induced protein oxidation, even if the drug itself induces protein oxidation.
An aldehydic product of lipid peroxidation, HNE, covalently modi¢es proteins inducing changes in conformation [64] and cross-linking [65, 66] , while causing diminished enzymatic activity [67^70] . Indeed, the cytotoxicity of HNE is well established [10, 71, 72] . Because levels of HNE, both free and bound, are increased in AD [19^23] and because AL has been shown to increase the levels of HNE in cells and synaptosomes [15, 17] , it has been suggested that HNE partially mediates the toxicity of AL [15^17]. Further, HNE has been shown to be increased in the neuronal damage associated with an ischemic injury. For example, Yoshino et al. demonstrated HNE-positive immunostaining within the infarcted area that results from ischemia/reperfusion injury [73] . Considering the evidence supporting a role for HNE and lipid peroxidation in neurodegeneration, therapeutics that target the protection of membrane lipids in disorders associated with oxidative stress may prove most bene¢cial.
These current results support the notion that U101033E is a potent free radical scavenger that attenuates lipid peroxidation occurring deep within the lipid bilayer. That U101033E can prevent the peroxidation of lipids, and likely HNE formation, in synaptosomes has profound relevance for neuronal degeneration, which is thought to originate at the synapse [74] . Indeed, the prevention of HNE formation and subsequent toxicity may be a key to the protection a¡orded by U101033E. Levels of HNE are increased after an ischemic insult [73] , neuronal cell death in ischemia is apoptotic [75, 76] and HNE has been shown to mediate oxidative stress-induced apoptosis [77] . These studies also support the notion that U101033E, possibly by way of its radical donating ability, initiates protein oxidation. As stated above, the concentrations of U101033E that result in oxidation or cross-linking of proteins are unlikely in a clinical scenario, however, one must remain cautious of these e¡ects. This oxidation may result in the inactivation of proteins and enzymes critical for a neuronal response to injury, and in this sense U101033E may be more problematic than therapeutic. Thus, one must weigh the bene¢ts of protection from lipid peroxidation against the possibility of increased protein oxidation when considering U101033E as a potential drug candidate.
